BCL6 represses CCND2 and MYC [27–29, 43]; we have recently shown that MYC expression levels significantly impact the prognosis of MYC rearranged DLBCL [44], and our multivariate analysis suggested BCL6 expression correlated with favorable survival (P = 0.048 for OS and P = 0.016 for PFS, Table 1), therefore the adverse prognostic impact of MYC might have been diminished by high BCL6 expression in these cases. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.